Is anyone aware of the reason that Rresverlogix is apparently pursuing the development of RVX-297 rather than apabetalone for the treatment of many inflammatory and autoimmune conditions?  Both are BD2-selective (but not BRD-selective) inhibitors and downregulate many of the same pro-inflammatory cytokines (e.g. Il6, TNFalpha, IFNgamma, Il17A) involved in inflammation and immunity.  In this publication outlining the effectiveness of RVX-297 in reducing pro-inflammatory gene expression (and protein production and disease pathology) in animal models of autoimmune disease http://molpharm.aspetjournals.org/content/molpharm/early/2017/09/29/mol.117.110379.full.pdf   the authors mention apabetalone as another BD2-selective BETi but do not specify why it was not also tested.  Different tissue distribution of drug activity is a possibility…